I TUOI DATI
I TUOI ORDINI
N. prodotti: 0
Totale ordine: € 0,00
I TUOI ABBONAMENTI
I TUOI ARTICOLI
THE JOURNAL OF CARDIOVASCULAR SURGERY
Rivista di Chirurgia Cardiaca, Vascolare e Toracica
Indexed/Abstracted in: BIOSIS Previews, Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,632
ORIGINAL ARTICLES THORACIC SECTION
The Journal of Cardiovascular Surgery 2011 August;52(4):613-9
Combined treatment of non-small cell lung cancer with synchronous brain metastases: a single center experience
Melloni G. 1, Bandiera A. 1, Gregorc V. 2, Carretta A. 1, Ciriaco P. 1, Viganò M. G. 2, Franzin A. 3, Bolognesi A. 4, Picozzi P. 3, Zannini P. 1 ✉
1 Department of Thoracic Surgery, San Raffaele Scientific Institute, Milan, Italy;
2 Department of Oncology, San Raffaele Scientific Institute, Milan, Italy;
3 Department of Neurosurgery, San Raffaele Scientific Institute, Milan, Italy;
4 Department of Radiotherapy, San Raffaele Scientific Institute, Milan, Italy
AIM :The aim of this study was to analyze our experience with combined treatment of non-small cell lung cancer with synchronous brain metastases.
METHODS: Between 1992 and 2008, 31 patients were treated by performing neurosurgery (or stereotactic radiosurgery) and lung surgery. Patients were divided into two groups according to their preoperative mediastinal work-up: group A (CT scan) and group B (FDG-PET scan).
RESULTS:Twenty-six patients had one brain metastasis and five had two. Neurosurgery was performed in 10 patients, stereotactic radiosurgery in 20 and both approaches in 1. Seven patients underwent chemotherapy after cerebral procedure. Pulmonary resection was complete in 27 cases and incomplete in 4. Histological findings showed: adenocarcinoma in 19 cases, squamous cell carcinoma in 8 and large cell carcinoma in 4. All patients underwent adjuvant chemotherapy. Overall 1, 2 and 5-year survival rates were 83%, 47% and 21%, respectively. The median survival was 22 months. Univariate analysis showed a better prognosis for complete resection (P=0.008), adenocarcinomas (P=0.015), N0 disease (P=0.038), and Group B (P=0.045). Multivariate analysis showed that only the radicality of the resection (P=0.027) and Group B (P=0.047) were independent prognostic factors.
CONCLUSION: Our experience confirms that selected patients with non-small cell lung cancer and synchronous brain metastases may be effectively treated by combined therapy. Complete resection, adenocarcinoma histology and N0 disease were prognostic factors. The incorporation of FDG-PET scan into the preoperative work-up may translate into a survival benefit.